Related Experiment Video
Updated: Mar 4, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in
Stephanie Wittig-Blaich1,2, Rainer Wittig1,3, Steffen Schmidt4,5
1Former Affiliation: Department of Molecular Genome Analysis, German Cancer Research Center (DKFZ), 69118 Heidelberg, Germany.
Abstract:
Next-generation sequencing has dramatically increased genome-wide profiling options and conceptually initiates the possibility for personalized cancer therapy. State-of-the-art sequencing studies yield large candidate gene sets comprising dozens or hundreds of mutated genes. However, few technologies are available for the systematic downstream evaluation of these results to identify novel starting points of future cancer therapies.We improved and extended a site-specific recombination-based system for systematic analysis of the individual functions of a large number of candidate genes. This was facilitated by a novel system for the construction of isogenic constitutive and inducible gain- and loss-of-function cell lines. Additionally, we demonstrate the construction of isogenic cell lines with combinations of the traits for advanced functional in vitro analyses. In a proof-of-concept experiment, a library of 108 isogenic melanoma cell lines was constructed and 8 genes were identified that significantly reduced viability in a discovery screen and in an independent validation screen. Here, we demonstrate the broad applicability of this recombination-based method and we proved its potential to identify new drug targets via the identification of the tumor suppressor DUSP6 as potential synthetic lethal target in melanoma cell lines with BRAF V600E mutations and high DUSP6 expression.
Insights
We developed a novel system for analyzing gene function in cancer, enabling the discovery of new drug targets. This method identified DUSP6 as a potential synthetic lethal target in melanoma, advancing personalized cancer therapy.
Area of Science:
- Genomics
- Cancer Biology
- Molecular Biology
Background:
- Next-generation sequencing generates large gene sets for cancer therapy.
- Systematic evaluation of these candidate genes is crucial for identifying new therapeutic targets.
- Current technologies for downstream functional analysis of numerous genes are limited.
Purpose of the Study:
- To improve and extend a recombination-based system for systematic gene function analysis.
- To develop a novel system for constructing isogenic gain- and loss-of-function cell lines.
- To demonstrate the potential of this method for identifying novel cancer drug targets.
Main Methods:
- A site-specific recombination-based system was enhanced for systematic gene analysis.
- Isogenic constitutive and inducible gain- and loss-of-function cell lines were constructed.
- A library of 108 isogenic melanoma cell lines was created for proof-of-concept screening.
Main Results:
- Eight genes significantly reducing cell viability were identified in both discovery and validation screens.
- The system demonstrated broad applicability for functional in vitro analyses.
- DUSP6 was identified as a potential synthetic lethal target in BRAF V600E-mutated melanoma cell lines.
Conclusions:
- The improved recombination-based system facilitates systematic functional gene analysis.
- This method is effective for identifying novel drug targets in cancer.
- DUSP6 represents a promising therapeutic target for specific melanoma subtypes.
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity
02:21Cancers Originate from Somatic Mutations in a Single Cell